Do NSAIDs and Other Pain Relief Drugs Can Inhibit the Growth of Lactobacillaceae ?
, e | 16 dic 2023
INFORMAZIONI SU QUESTO ARTICOLO
Article Category: SHORT COMMUNICATION
Pubblicato online: 16 dic 2023
Pagine: 507 - 513
Ricevuto: 04 lug 2023
Accettato: 13 set 2023
DOI: https://doi.org/10.33073/pjm-2023-038
Parole chiave
© 2023 Hanna Kruszewska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The summary of activity in vitro of tested NSAIDs and analgesics against Lactobacillaceae strains.
| Active substance | The lowest inhibitory concentration for a minimum 2 strains |
|---|---|
| Nabumetone | > 3.2 mg/ml |
| Celecoxib | > 3.2 mg/ml |
| Nimesulide | > 3.2 mg/ml |
| Meloxicam | > 3.2 mg/ml |
| Etoricoxib | > 3.2 mg/ml |
| Naproxen | > 3.2 mg/ml |
| Piroxicam | > 3.2 mg/ml |
| Indomethacin | > 3.2 mg/ml |
| Tramadol | > 3.2 mg/ml |
| Paracetamol | > 3.2 mg/ml |
| Acetylsalicylic acid | 3.2 mg/ml |
| Ketoprofen | 0.8 mg/ml |
| Dexketoprofen | 0.8 mg/ml |
| Ibuprofen | 0.4 mg/ml |
| Flurbiprofen | 0.4 mg/ml |
| Diclofenac | 0.05 mg/ml |
Minimal inhibitory concentration (MIC) of selected NSAIDs against 49 Lactobacillaceae strains.
| Species | Source/(number of strains) | MIC (mg/ml) | Acetylsalicylic acid | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Flurbiprofen | Ketoprofen | Dexketoprofen | Ibuprofen | Diclofenac | |||||||||||||||
| 0.4 | 0.8 | 1.6 | 3.2 | 0.8 | 1.6 | 3.2 | 0.8 | 1.6 | 3.2 | 0.4 | 0.8 | 1.6 | 0.05 | 0.1 | 0.2 | 0.8 | 3.2 | ||
| ATCC* 4356™ | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| Probiotic products (n = 10) | 4 | 2 | 4 | 0 | 0 | 9 | 1 | 0 | 9 | 1 | 2 | 5 | 3 | 0 | 5 | 2 | 3 | 10 | |
| Clinical isolates (n = 9) | 0 | 4 | 5 | 0 | 0 | 6 | 3 | 0 | 4 | 5 | 1 | 8 | 0 | 0 | 4 | 5 | 0 | 9 | |
| ATCC* 53103™ | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | |
| Probiotic products (n = 4) | 1 | 3 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 4 | 0 | 4 | 0 | 0 | 1 | 3 | 0 | 4 | |
| Clinical isolates (n = 6) | 0 | 0 | 5 | 1 | 0 | 0 | 6 | 0 | 1 | 5 | 0 | 6 | 0 | 0 | 4 | 2 | 0 | 6 | |
| Probiotic products (n = 4) | 2 | 2 | 0 | 0 | 0 | 3 | 1 | 0 | 4 | 0 | 4 | 0 | 0 | 1 | 3 | 0 | 0 | 4 | |
| Clinical isolates (n = 2) | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | |
| Probiotic products (n = 3) | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 1 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | |
| ATCC* 14917™ | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| Probiotic products (n = 3) | 0 | 3 | 1 | 0 | 1 | 2 | 0 | 0 | 3 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | |
| Clinical isolates (n = 4) | 0 | 2 | 1 | 0 | 0 | 4 | 0 | 0 | 4 | 0 | 1 | 3 | 0 | 0 | 3 | 1 | 0 | 4 | |
| Probiotic products (n= 1) | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| TOTAL | 49 | 9 | 22 | 17 | 1 | 4 | 29 | 16 | 4 | 29 | 16 | 19 | 27 | 3 | 2 | 30 | 14 | 3 | 49 |